[DDAVP in the treatment of acute neurosurgical diabetes insipidus].
The effects of a synthetic vasopressin analogue, DDAVP (1-deamino-8-d- arginine-vasopressin) were studied in 5 adults and 2 children with acute central diabetes insipidus secondary to neurosurgery. 5 mcg DDAVP was administered intranasally twice a day to the two children, whereas the adults received the drug i.m. (1 mcg twice a day, 3 patients; 1 mcg once a day, 1 patient; 4 mcg twice a day, 1 patient). All subjects displayed an early, prolonged response (12-24 hr). There were no side-effects. The effectiveness of DDAVP, its prolonged action, and virtual freedom from side-effects when given intranasally or parenterally make it the drug of choice in the treatment of acute neurosurgical diabetes insipidus.
D000293:Adolescent; D000328:Adult; D001127:Arginine Vasopressin / Q000627:therapeutic use*; D002557:Cerebrospinal Fluid Shunts / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use*; D003919:Diabetes Insipidus / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009994:Osmolar Concentration; D013046:Specific Gravity; D014556:Urine / Q000032:analysis
D001127:Arginine Vasopressin; D003894:Deamino Arginine Vasopressin
Il DDAVP nel trattamento del diabete insipido neurochirurgico acuto.